Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312795145> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4312795145 endingPage "S386" @default.
- W4312795145 startingPage "S386" @default.
- W4312795145 abstract "Background: Pancreatic cancer continues to be a major cause of cancer-related mortality. There has been a greater implementation of upfront chemotherapy for pancreatic adenocarcinoma patients. Although there are many theoretical benefits to neoadjuvant chemotherapy, its clinical impact is uncertain. We sought to understand the outcomes of patients with resectable and borderline-resectable pancreatic adenocarcinoma who undergo neoadjuvant chemotherapy. Methods: Patients were collected in a secure database from September 2018 to May 2020. Patients were excluded if they presented with locally advanced or metastatic disease, inability to complete chemotherapy or if they were not a surgical candidate. Anatomic resectability was determined by the 2017 International Consensus Definition. Results: 66 patients with resectable disease underwent chemotherapy. FOLFIRINOX was used in 41 (62%) patients, gemcitabine-based regimens in 28 (42%) patients (total greater than 100% as some patients underwent both regimens). Following re-staging, 47 patients (71.2%) were thought to have resectable disease. Of these patients, 36 have been successfully resected to date. Metastatic disease was found in 12 patients (18.2%) and 6 patients (9.1%) had locally advanced disease. Conclusion: Most patients with resectable pancreatic cancer are resected after neoadjuvant chemotherapy, but a subset will develop local or distant progression. Further studies will be needed to determine which patients will progress locally and may benefit from an upfront surgical approach." @default.
- W4312795145 created "2023-01-05" @default.
- W4312795145 creator A5021909013 @default.
- W4312795145 creator A5046990205 @default.
- W4312795145 creator A5047222255 @default.
- W4312795145 creator A5051654669 @default.
- W4312795145 creator A5069982476 @default.
- W4312795145 creator A5070470634 @default.
- W4312795145 creator A5076908226 @default.
- W4312795145 date "2022-01-01" @default.
- W4312795145 modified "2023-09-28" @default.
- W4312795145 title "The Fate of Resectable Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy" @default.
- W4312795145 doi "https://doi.org/10.1016/j.hpb.2022.05.819" @default.
- W4312795145 hasPublicationYear "2022" @default.
- W4312795145 type Work @default.
- W4312795145 citedByCount "0" @default.
- W4312795145 crossrefType "journal-article" @default.
- W4312795145 hasAuthorship W4312795145A5021909013 @default.
- W4312795145 hasAuthorship W4312795145A5046990205 @default.
- W4312795145 hasAuthorship W4312795145A5047222255 @default.
- W4312795145 hasAuthorship W4312795145A5051654669 @default.
- W4312795145 hasAuthorship W4312795145A5069982476 @default.
- W4312795145 hasAuthorship W4312795145A5070470634 @default.
- W4312795145 hasAuthorship W4312795145A5076908226 @default.
- W4312795145 hasBestOaLocation W43127951451 @default.
- W4312795145 hasConcept C121608353 @default.
- W4312795145 hasConcept C126322002 @default.
- W4312795145 hasConcept C141071460 @default.
- W4312795145 hasConcept C143998085 @default.
- W4312795145 hasConcept C2776694085 @default.
- W4312795145 hasConcept C2777148230 @default.
- W4312795145 hasConcept C2778292576 @default.
- W4312795145 hasConcept C2779134260 @default.
- W4312795145 hasConcept C2780210213 @default.
- W4312795145 hasConcept C2780258809 @default.
- W4312795145 hasConcept C2780259306 @default.
- W4312795145 hasConcept C2781182431 @default.
- W4312795145 hasConcept C526805850 @default.
- W4312795145 hasConcept C530470458 @default.
- W4312795145 hasConcept C71924100 @default.
- W4312795145 hasConceptScore W4312795145C121608353 @default.
- W4312795145 hasConceptScore W4312795145C126322002 @default.
- W4312795145 hasConceptScore W4312795145C141071460 @default.
- W4312795145 hasConceptScore W4312795145C143998085 @default.
- W4312795145 hasConceptScore W4312795145C2776694085 @default.
- W4312795145 hasConceptScore W4312795145C2777148230 @default.
- W4312795145 hasConceptScore W4312795145C2778292576 @default.
- W4312795145 hasConceptScore W4312795145C2779134260 @default.
- W4312795145 hasConceptScore W4312795145C2780210213 @default.
- W4312795145 hasConceptScore W4312795145C2780258809 @default.
- W4312795145 hasConceptScore W4312795145C2780259306 @default.
- W4312795145 hasConceptScore W4312795145C2781182431 @default.
- W4312795145 hasConceptScore W4312795145C526805850 @default.
- W4312795145 hasConceptScore W4312795145C530470458 @default.
- W4312795145 hasConceptScore W4312795145C71924100 @default.
- W4312795145 hasLocation W43127951451 @default.
- W4312795145 hasOpenAccess W4312795145 @default.
- W4312795145 hasPrimaryLocation W43127951451 @default.
- W4312795145 hasRelatedWork W2012954058 @default.
- W4312795145 hasRelatedWork W2333414779 @default.
- W4312795145 hasRelatedWork W2376347278 @default.
- W4312795145 hasRelatedWork W2599910524 @default.
- W4312795145 hasRelatedWork W2910998150 @default.
- W4312795145 hasRelatedWork W3008650849 @default.
- W4312795145 hasRelatedWork W3029364823 @default.
- W4312795145 hasRelatedWork W3042208798 @default.
- W4312795145 hasRelatedWork W3046481916 @default.
- W4312795145 hasRelatedWork W3196960728 @default.
- W4312795145 hasVolume "24" @default.
- W4312795145 isParatext "false" @default.
- W4312795145 isRetracted "false" @default.
- W4312795145 workType "article" @default.